NVAX - Novavax, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.5283
+0.0067 (+1.28%)
At close: 4:00PM EDT

0.5000 -0.03 (-5.36%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close0.5216
Open0.5250
Bid0.5201 x 4000
Ask0.5225 x 800
Day's Range0.5150 - 0.5500
52 Week Range0.4900 - 2.5800
Volume8,942,183
Avg. Volume16,908,406
Market Cap248.013M
Beta (3Y Monthly)2.22
PE Ratio (TTM)N/A
EPS (TTM)-0.5000
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.46
Trade prices are not sourced from all markets
  • Benzinga6 days ago

    The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...

  • Novavax faces delisting threat following failed drug trial
    American City Business Journals7 days ago

    Novavax faces delisting threat following failed drug trial

    Nasdaq has warned Novavax Inc. that its stock could be delisted if it can’t get the price consistently above a buck within the next six months. The Gaithersburg biotech’s stock has fallen below $1 for 30 consecutive days and the company has 180 days — until Oct. 8 — to regain compliance by getting its common stock bid price up for at least 10 consecutive business days. Novavax plans to hold a special stockholder meeting May 8 to consider a reverse stock split, according to public filings.

  • Benzinga9 days ago

    The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

    Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. (NASDAQ: AMGN )'s unique drug to treat osteoporosis in postmenopausal women ...

  • ACCESSWIRE10 days ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Novavax, Inc.

    NEW YORK, NY / ACCESSWIRE / April 12, 2019 / Levi & Korsinsky announces it has commenced an investigation of Novavax, Inc. (NASDAQ: NVAX) concerning possible breaches of fiduciary duty. To obtain additional ...

  • Novavax (NVAX) Stock Moves -0.67%: What You Should Know
    Zacks11 days ago

    Novavax (NVAX) Stock Moves -0.67%: What You Should Know

    In the latest trading session, Novavax (NVAX) closed at $0.57, marking a -0.67% move from the previous day.

  • GlobeNewswire13 days ago

    Novavax Scientific Leadership to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD at World Vaccine Congress

    GAITHERSBURG, Md., April 09, 2019 -- Novavax, Inc. (NASDAQ: NVAX) today announced that Gregory M. Glenn, M.D., President of Research and Development, will share data from its.

  • Thomson Reuters StreetEvents17 days ago

    Edited Transcript of NVAX earnings conference call or presentation 18-Mar-19 8:30pm GMT

    Q4 2018 Novavax Inc Earnings Call

  • Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
    Zacks17 days ago

    Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, Novavax (NVAX) closed at $0.59, marking a +1.57% move from the previous day.

  • Novavax (NVAX) Gains As Market Dips: What You Should Know
    Zacks26 days ago

    Novavax (NVAX) Gains As Market Dips: What You Should Know

    In the latest trading session, Novavax (NVAX) closed at $0.53, marking a +0.21% move from the previous day.

  • ACCESSWIRE26 days ago

    Four Healthcare Stocks Picking Up Speed on Wednesday

    CORAL GABLES, FL / ACCESSWIRE / March 27, 2019 / The future of the healthcare stock market is directly correlated to whether companies in the healthcare sector have what it takes to meet the growing health challenges facing society. According to recent statistics, global shortages in primary care physicians coupled with rising populations has left millions without access to acute care. Luckily, there are healthcare companies rising to the challenge with innovative medical technologies and nuanced approaches to how we treat and care for our patients.

  • 3 Cheap Stocks to Buy That Are Worth Every Penny
    InvestorPlacelast month

    3 Cheap Stocks to Buy That Are Worth Every Penny

    So close, and yet so far. That sums up the state of the markets recently, with investors jittery over the sudden chill surrounding U.S.-China relations. In an about-face on the trade dispute, President Trump conceded that tariffs on Chinese goods may remain for a "substantial period of time." Simultaneously, this hurts the broader markets but it also raises prospects for cheap stocks.I know what you're thinking: why should I consider cheap stocks to buy when blue-chip names are also available for deeply discounted prices? Far be it from me to disagree with that logic. Typically, you accrue the biggest profits from striking while others are panicking. But after you're comfortable with your high-probability bets, penny stocks provide exceptionally robust return potential.We should also discuss the "under-the-radar" argument. News such as the trade-war dispute disproportionately hurt the blue chips because they're usually multinational corporations with global vulnerabilities. While penny stocks also suffer the trickle-down effect, they're more likely to move on sector-specific developments.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 10 Best ETFs to Buy in the Second Quarter With that in mind, let's take a look at three (very) cheap stocks to buy that are worth every penny: Entree Resources (EGI)Source: Jeremy Vohwinkle via Flickr (Modified)Entree Resources (NYSEAMERICAN:EGI) is one of the penny stocks that actually benefits from broader and sector-specific trends. With all eyes focused on the suddenly deteriorating trade-war dispute, investors get nervous. When investors get nervous, they buy gold. Naturally, as a gold miner, EGI has a lot to gain.Another thing that intrigued me about EGI as a candidate for cheap stocks to buy is its locality. Most speculative miners have projects in extremely unstable countries just begging for nationalization. While Entree's main property in Mongolia isn't the greatest region for stability, it's also not the worst. Over the last few years, Mongolia improved its standing for ease of doing business.Additionally, the gold price has also improved, gaining roughly 10% since the first of October. That's a net positive for EGI stock, especially since it might go higher still. However, keep in mind that gold is extremely volatile, so don't lever yourself excessively. Genius Brands International (GNUS)Source: Shutterstock The entertainment industry is a tough sector in which to survive, let alone thrive. What works and what doesn't often seem arbitrary. Moreover, maintaining relevance is a gargantuan task once you've accomplished the already difficult task of delivering a hit. But the prospect of finding that hit drives Genius Brands International (NASDAQ:GNUS).GNUS specializes in creating compelling content and characters. Where it differs compared to other cheap stocks in the entertainment field is the company's core audience: toddlers to tweens. This is an exceptionally challenging market to crack because you're dealing with two audiences: the young consumer and their parents/guardians. * 10 Stocks on the Rise Heading Into the Second Quarter At the same time, GNUS has a viable pathway to profound growth. The reason? Brands such as cartoon characters translate very well internationally. If it resonates in America, it will probably resonate everywhere else. Novavax (NVAX)Source: Shutterstock Over the past few years, vaccination captured the public's attention, and not always in a good way. With President Trump's election, an increasing number of people became aware of so-called alternative-truth movements. Many of these right-leaning organizations rally fiercely against vaccination, particularly government-imposed protocols.On the surface, that doesn't help Novavax (NASDAQ:NVAX), which specializes in the stuff. Nor does the fact that NVAX is one of the riskiest penny stocks to buy. Since Feb. 27, shares have plummeted nearly 71%. Even more concerning is the reason why NVAX fell.In a clinical trial, the company's NanoFlu treatment failed to beat placebo. In other words, positive thinking yielded roughly the same efficacy in preventing influenza than the vaccine.Given that NVAX is a fundamentally poor organization, I'm not surprised that shares fell. However, keep in mind that most Americans support vaccination. Therefore, the broader financial incentive to stay the course until efficacy improves is incredibly high.As of this writing, Josh Enomoto is long gold. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks That Will Continue to Rebound in 2019 * 5 Stocks To Buy for the Happiest Employees * 7 ETFs for a Millennial Portfolio Compare Brokers The post 3 Cheap Stocks to Buy That Are Worth Every Penny appeared first on InvestorPlace.

  • Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?
    Zackslast month

    Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?

    Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

  • Why Novavax Is Soaring Today
    Motley Foollast month

    Why Novavax Is Soaring Today

    Investors' optimism about the prospects for the biotech's experimental vaccines appears to be increasing.

  • Does Novavax Have a Viable Path Forward?
    Motley Foollast month

    Does Novavax Have a Viable Path Forward?

    Novavax needs a deep-pocketed partner soon.

  • What's Next for Novavax?
    Motley Foollast month

    What's Next for Novavax?

    The beleaguered biotech is down but not out.

  • Novavax (NVAX) Q4 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Novavax (NVAX) Q4 2018 Earnings Conference Call Transcript

    NVAX earnings call for the period ending December 31, 2018.

  • Associated Presslast month

    Novavax: 4Q Earnings Snapshot

    The Gaithersburg, Maryland-based company said it had a loss of 13 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • GlobeNewswirelast month

    Novavax Reports Fourth Quarter and Year-End 2018 Financial Results

    GAITHERSBURG, Md., March 18, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months.

  • Benzingalast month

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

    Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support. Here are some key catalysts that can move biotech stocks in the ...

  • ACCESSWIRElast month

    These Four Healthcare Stocks Are Making Moves on Wednesday

    CORAL GABLES, FL / ACCESSWIRE / March 13, 2019 / The healthcare stock market has managed to attract significant attention in the initial months of 2019 as a result of healthcare companies demonstrating to investors and consumers their commitment to the future of the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Novavax Inc (NVAX), Advaxis Inc (ADXS), and MannKind Corporation (MNKD) are 4 healthcare companies raising the bar on Wednesday. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care.

  • ACCESSWIRElast month

    These Four Healthcare Stocks are Surging with Potential

    CORAL GABLES, FL / ACCESSWIRE / March 12, 2019 / The healthcare stock market is comprised of innovative companies working diligently to design, manufacture, and commercialize state-of-the-art tech-driven solutions for the healthcare industry. It is the responsibility of healthcare companies to meet the oncoming challenges presented by infectious diseases and ailments, and so long as they can meet these requirements, the healthcare sector could generate market excitement. Premier Health Group (OTC:PHGRF) (CSE:PHGI), ENDRA Life Sciences Inc (NDRA), Novavax Inc (NVAX), and Aevi Genomic Medicine Inc (GNMX) are 4 healthcare companies raising the bar on Tuesday.

  • GlobeNewswirelast month

    Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results on March 18, 2019

    GAITHERSBURG, Md., March 11, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter 2018 financial and operating results prior to U.S. financial.

  • ACCESSWIRElast month

    The Device Market That Drove One Company From $2.50 to $65 Has a New Entrant

    The move to get patients out of doctors offices and hospitals quickly using virtual care and remote monitoring is underway. Technology is enabling the switch, and few sub-sectors have benefited more than remote cardiac care. Companies like Biotelemetry (BEAT) have grown by leaps and bounds in the last few years as their proprietary remote cardiac monitoring devices have gained traction.

  • Is a Beat in Store for Catabasis (CATB) This Earnings Season?
    Zacks2 months ago

    Is a Beat in Store for Catabasis (CATB) This Earnings Season?

    Catabasis (CATB) progresses with DMD candidate, edasalonexent. However, operating expenses are likely to be lower.

  • ACCESSWIRE2 months ago

    Four Healthcare Stocks Seeing Gains On Wednesday

    At the end of the day, our health is our key priority, and it is the responsibility of the healthcare industry to meet the growing demands of consumers as more diseases are discovered. Interestingly enough, amid this responsibly lies the opportunity for healthcare companies to unlock lucrative potential and attract investors to the space. If companies in the healthcare sector continue to take creative approaches to design drug treatments and care solutions, this will, in turn, improve the lives of consumers, thus catalyzing significant investor interest in the sector.